The past three decades have witnessed substantial transformations in PCa epidemiology, driven by innovations in diagnostic modalities, prostate-specific antigen (PSA) screening protocols, and persistent disparities in healthcare accessibility (3, 4). Here, KLK3 is linked to posterior cortical atrophy.